Comparing Endonovo Therapeutics (OTCMKTS:ENDV) and Sana Biotechnology (NASDAQ:SANA)

Sana Biotechnology (NASDAQ:SANA) and Endonovo Therapeutics (OTCMKTS:ENDV) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, valuation and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Sana Biotechnology and Endonovo Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	1	1	7	0	2.67
Endonovo Therapeutics	0	0	0	0	0.00

Sana Biotechnology presently has a consensus target price of $9.50, suggesting a potential upside of 179.41%. Given Sana Biotechnology’s stronger consensus rating and higher probable upside, equities analysts clearly believe Sana Biotechnology is more favorable than Endonovo Therapeutics.

Profitability

This table compares Sana Biotechnology and Endonovo Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-108.01%	-40.68%
Endonovo Therapeutics	N/A	N/A	N/A

Insider & Institutional Ownership

88.2% of Sana Biotechnology shares are held by institutional investors. 25.4% of Sana Biotechnology shares are held by insiders. Comparatively, 5.6% of Endonovo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

Sana Biotechnology has a beta of 2.16, meaning that its stock price is 116% more volatile than the S&P 500. Comparatively, Endonovo Therapeutics has a beta of -1.03, meaning that its stock price is 203% less volatile than the S&P 500.

Valuation & Earnings

This table compares Sana Biotechnology and Endonovo Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$244.17 million	($0.93)	-3.66
Endonovo Therapeutics	$10,000.00	14.46	-$2.18 million	N/A	N/A

Endonovo Therapeutics has higher revenue and earnings than Sana Biotechnology.

Summary

Sana Biotechnology beats Endonovo Therapeutics on 6 of the 10 factors compared between the two stocks.

About Sana Biotechnology

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company’s product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin’s lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam’s proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

About Endonovo Therapeutics

Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of cardiovascular diseases, chronic kidney, liver diseases, non-alcoholic steatohepatitis, cardiovascular and peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post-concussion syndrome, stroke, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.